BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT · NASDAQ Global Market
+$0.29 today
Vol 0.38M · Avg 0.35M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:BBOT · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$154.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-5.71, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $121.2M +65.8% | $73.1M +29.9% | $56.3M | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $24.6M +217.4% | $7.8M -8.6% | $8.5M +240951.1% | $3.5K -91.9% | $43.4K | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $145.8M +80.3% | $80.9M +24.8% | $64.8M +1839985.2% | $3.5K -91.9% | $43.4K | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $610.0K +193.3% | $208.0K +126.1% | $92.0K +2513.6% | $3.5K -95.3% | $74.3K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$145.2M -80.0% | -$80.7M -24.7% | -$64.7M -1837371.6% | -$3.5K +91.9% | -$43.4K | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$145.8M -80.3% | -$80.9M -24.8% | -$64.8M -1839985.2% | -$3.5K +91.9% | -$43.4K | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $11.3M +34.1% | $8.5M +11643.7% | $72.0K | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $11.8M +43.9% | $8.2M +11266.5% | $72.0K | $0 | $0 | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$134.0M -80.5% | -$74.3M -14.8% | -$64.7M -1837939.8% | -$3.5K +91.9% | -$43.4K | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$134.0M -80.5% | -$74.3M -14.8% | -$64.7M -1837939.8% | -$3.5K +91.9% | -$43.4K | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 -1034.8% | $0 +114.6% | -$3 -1580100.0% | $0 +109.5% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 -1034.8% | $0 +114.6% | -$3 -1579900.0% | -$0 +90.5% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $31.1M +87.2% | $16.6M -18.8% | $20.5M +0.0% | $20.5M +0.0% | $20.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $31.1M +87.2% | $16.6M -18.8% | $20.5M +0.0% | $20.5M +0.0% | $20.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.45B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
Oculis Holding AG
NASDAQ:OCS
$634.01M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BBOT generate?
BridgeBio Oncology Therapeutics Inc. (BBOT) reported $0.00 of revenue in fiscal 2025.
Is BBOT profitable?
BridgeBio Oncology Therapeutics Inc. (BBOT) reported -$134,044,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.